Ebv-Specific Transfer Factor in the Treatment of Abdominal Burkitt’s Lymphoma in Ghana, West Africa

Although endemic Burkitt’s lymphoma (BL) is particularly responsive to chemotherapy, approximately 50 percent of patients with abdominal (stage III) tumour relapse despite complete remission after initial therapy. Relapse adversely affects the prognosis. Two patterns of relapse in endemic Burkitt’s lymphoma have been documented in Ghana,(1) Early relapse (i.e. relapse within 12 weeks of clinically induced complete remission) may occur. This most likely represents regrowth of the original tumour not completely controlled by induction chemotherapy. Relapse beyond 12 weeks are considered as late relapses and most likely occur as a result of disease re-induction.